Drugs / CIML NK Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03068819 | Oct 2017 → Jun 2025 | acute myeloid leukemia | Washington University School of Medicine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-03 | Wugen, Inc. | Results Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting wugen.com ↗
Further analysis also identified an 8-gene TME signature score that was significantly higher at baseline in patients with R/R AML that responded to CIML NK cell therapy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-03 | Wugen, Inc. | Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting wugen.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIML NK Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068819 ↗ |
| Modality | Cell therapy | “infusion of donor lymphocytes and ML NK cells from the original HCT donor” PMID 34871371 ↗ Mar 2022 |
| Route | Other | “infusion of donor lymphocytes and ML NK cells from the original HCT donor” PMID 34871371 ↗ Mar 2022 |